Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28392768 | 1.00 | MAOB (0.43) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL28394138 | 1.00 | MAOB (0.43) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL904863 | 0.83 | MAOB (0.41) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL2974161 | 0.79 | MAOB (0.39) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL6214674 | 0.79 | MAOB (0.39) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL30824592 | 0.79 | CA2 (0.41) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL140190 | 0.79 | CA2 (0.41) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL24898027 | 0.79 | MAOB (0.43) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL4152831 | 0.79 | MAOB (0.47) | MAOBHSD17B2MAOAPTPN1PSMB5 | |
| SCHEMBL5240004 | 0.79 | LMNA (0.44) | MAOBHSD17B2MAOAPTPN1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930620-A | Tetrafused ring compound, preparation method, pharmaceutical composition and application thereof | 和径医药科技（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-110997663-A | Benzofuran ureas or carbamates and heteroaromatic analogs thereof for use in therapy | 欧洲分子生物学实验室 | 2020-04-10 | — | — | CN | disclosed |
| US-7776848-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| EP-1778680-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1778680-A2 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018184-A2 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213351-A1 | Spirocyclic cyclohexane compounds | PKD1, PKD2, NR3C2 | MAOB 1870/4885HSD17B2 34/4885MAOA 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.